Edgar Filing: DUSA PHARMACEUTICALS INC - Form 4

	Lugari					
DUSA PHA Form 4 May 15, 200	RMACEUTICALS INC					
FORN Check thi if no long subject to Section 1 Form 4 o Form 5 obligation may cont <i>See</i> Instru 1(b).	14 UNITED STATE is box ger 6. r finue. inteinue. Section 17(a) of the 30(b)	CS SECURITIES AND EXCHANGE (Washington, D.C. 20549 OF CHANGES IN BENEFICIAL OW SECURITIES • Section 16(a) of the Securities Exchang • Public Utility Holding Company Act of •) of the Investment Company Act of 194	NERSHIP OF NERSHIP OF a Act of 1934, f 1935 or Section Number: 3235-0287 Number: January 31, 2005 Estimated average burden hours per response 0.5			
(Print or Type F	Responses)					
1. Name and A MOLITEUS	ddress of Reporting Person <u>*</u> MAGNUS	2. Issuer Name and Ticker or Trading Symbol DUSA PHARMACEUTICALS INC [DUSA]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Last) 958 SUNSE	(First) (Middle) T RIDGE	3. Date of Earliest Transaction (Month/Day/Year) 05/14/2007	X_ Director10% Owner Officer (give titleOther (specify below) below)			
	(Street)	4. If Amendment, Date Original Filed(Month/Day/Year)	6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person			
	ATER, NJ 08807		Form filed by More than One Reporting Person			
(City)	(State) (Zip)	Table I - Non-Derivative Securities Acc	uired, Disposed of, or Beneficially Owned			
1.Title of Security (Instr. 3)	2. Transaction Date 2A. De (Month/Day/Year) Execut any (Month	1	5. Amount of Securities6. Ownership Form: Direct7. Nature of IndirectBeneficially Owned(D) or Indirect (I)Beneficial OwnershipFollowing Transaction(s) (Instr. 3 and 4)(Instr. 4)			
Common Stock	05/14/2007	M 15,000 A ^{\$} 2.71	15,000 D			

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amou Underlying Secur (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Am or Nu of S
Non-Qualif Stock Optic	5 2 / 1	05/14/2007		М	15,000	08/24/2003	08/23/2013	Common Stock	15

Edgar Filing: DUSA PHARMACEUTICALS INC - Form 4

Reporting Owners

Reporting Owner Name / Address	ŝ	Relationships			
	Director	10% Owner	Officer	Other	
MOLITEUS MAGNUS 958 SUNSET RIDGE BRIDGEWATER, NJ 08807	Х				
Signatures					
/s/ Magnus Moliteus	5/14/2007				
<u>**</u> Signature of Reporting Person	Date				

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.